Physician profile
Larry T Olinde
NPI 1720074453
$4,001.92
in general payments reported to CMS, 2019-2025
19 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $111 · 2021: $359 · 2022: $891 · 2023: $900 · 2024: $844 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.35 |
| Education | $184.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,078.36 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $759.31 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $439.46 | 2019-2024 | Velphoro, Korsuva |
| Akebia Therapeutics INC | $378.86 | 2019-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $329.96 | 2019-2025 | Rayaldee |
| Amgen INC. | $226.92 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $197.50 | 2019-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $143.41 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $74.30 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $60.48 | 2023-2025 | |
| Abbvie INC. | $56.97 | 2024-2025 | |
| Novo Nordisk INC | $52.90 | 2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $49.44 | 2020-2023 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $48.56 | 2022-2024 | Jesduvroq, Benlysta |
| Scpharmaceuticals INC. | $28.05 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $27.93 | 2025 | Filspari |
| Lilly USA, LLC | $21.25 | 2024 | Mounjaro, Zepbound |
| Ardelyx, INC. | $14.53 | 2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Olinde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.